EC Number   |
Disease |
PubMed ID |
Title of Publication  |
Category |
Confidence Level |
|---|
    3.5.4.4 | adenosine deaminase deficiency |
29620681 |
"Immune" Thrombocytopenia as Key Feature of a Novel ADA2 Deficiency Variant: Implication on Differential Diagnostics of ITP in Children. |
causal interaction
unassigned |
4
0 |
| 3.5.4.4 | Thrombocytopenia |
29620681 |
"Immune" Thrombocytopenia as Key Feature of a Novel ADA2 Deficiency Variant: Implication on Differential Diagnostics of ITP in Children. |
causal interaction
unassigned |
4
0 |
| 3.5.4.4 | adenosine deaminase deficiency |
2597438 |
1-Methyladenine in urine of an adenosine deaminase-deficient adult without immunodeficiency. |
unassigned |
0 |
| 3.5.4.4 | Melanoma |
30548323 |
1?, 25-Dihydroxyvitamin D3 alters ectonucleotidase expression and activity in human cutaneous melanoma cells. |
ongoing research
unassigned |
4
0 |
| 3.5.4.4 | Hematologic Neoplasms |
8094002 |
2 chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms. |
unassigned |
0 |
| 3.5.4.4 | Leukemia |
6976833 |
2'-deoxycoformycin (DCF) and 9-beta-D-arabinofuranosyladenine (Ara-A) in the treatment of refractory acute myelocytic leukemia. |
diagnostic usage
therapeutic application
unassigned |
3
4
0 |
| 3.5.4.4 | Leukemia, Myeloid, Acute |
6976833 |
2'-deoxycoformycin (DCF) and 9-beta-D-arabinofuranosyladenine (Ara-A) in the treatment of refractory acute myelocytic leukemia. |
diagnostic usage
therapeutic application
unassigned |
3
4
0 |
| 3.5.4.4 | Severe Combined Immunodeficiency |
3097141 |
2'Deoxycoformycin and deoxyadenosine affect IL 2 production and IL 2 receptor expression of human T cells. |
causal interaction
unassigned |
4
0 |
| 3.5.4.4 | adenosine deaminase deficiency |
27463204 |
2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive Nucleoside. |
causal interaction
therapeutic application
unassigned |
4
1
0 |
| 3.5.4.4 | adenosine deaminase deficiency |
8099730 |
2-Chlorodeoxyadenosine in haematological malignancies. |
causal interaction
therapeutic application
unassigned |
4
1
0 |
